Histologic Lesions of Porto-Sinusoidal Vascular Disease Following Phlebotomy in Hemochromatosis

Background Phlebotomy induces regression of liver fibrosis in genetic hemochromatosis. We assessed the histologic changes in pre-phlebotomy and post-phlebotomy liver biopsies from patients with HFE mutation as a model to study regression of fibrosis. We aimed to show that phlebotomy-induced histologic lesions overlap with porto-sinusoidal vascular disease (PSVD, also known as idiopathic non-cirrhotic portal hypertension), histologically. Methods A total of 51 biopsies (22 pre-phlebotomy and 29 post-phlebotomy) were reviewed, and three variables were studied: iron index indicative of the amount of accumulated iron (range 0 to 18), the combined score of vascular changes reflecting the presence of histological lesions that are described in PSVD (range 0 to 9) and the high-grade shunt vessel by calculating the proportion of portal tracts with shunt vessels, with a cutoff of 50%. Two-tailed Student’s t-test and Fisher’s exact test were performed to compare the means of two variables and frequencies of the histologic lesions in two groups, respectively. A P-value < 0.05 was considered statistically significant. Results The iron index was higher in the pre-phlebotomy compared to post-phlebotomy group (P = 0.01). Compared to the pre-phlebotomy group, the combined score was higher in the post-phlebotomy group when the cases of advanced fibrosis were excluded (P = 0.023) and remained higher when patients with risk factors for PSVD were further excluded (P = 0.034). The high-grade shunt vessel tended to be more common in the post-phlebotomy group when advanced fibrosis was excluded; however, the statistical significance was marginal (P = 0.056). Conclusions Phlebotomy reduces hepatic iron load and induces histologic lesions of PSVD in patients with HFE mutation. Our data support a postulation that some of the histologic lesions of PSVD represent vascular remodeling following a regression of fibrosis and may not be reflective of risk factors or etiopathogenesis of PSVD. Regressed fibrosis and PSVD may not be reliably distinguished in a limited sample, therefore warranting cautious interpretation in the right clinical context.

[1]  V. Vilgrain,et al.  Porto-sinusoidal vascular disease: proposal and description of a novel entity. , 2019, The lancet. Gastroenterology & hepatology.

[2]  P. Hytiroglou,et al.  Regression of human cirrhosis: an update, 18 years after the pioneering article by Wanless et al. , 2018, Virchows Archiv.

[3]  Hwajeong Lee,et al.  Prevalence of histological features of idiopathic noncirrhotic portal hypertension in general population: a retrospective study of incidental liver biopsies , 2017, Hepatology International.

[4]  C. Author,et al.  Idiopathic Noncirrhotic Portal Hypertension: An Appraisal , 2015, Journal of pathology and translational medicine.

[5]  C. Mulder,et al.  Diagnosing Nodular Regenerative Hyperplasia of the Liver Is Thwarted by Low Interobserver Agreement , 2015, PloS one.

[6]  C. Sheehan,et al.  Histological Spectrum of Idiopathic Noncirrhotic Portal Hypertension in Liver Biopsies From Dialysis Patients , 2015, International journal of surgical pathology.

[7]  N. Petrosillo,et al.  Incomplete septal cirrhosis after high‐dose methylprednisolone therapy and regression of liver injury , 2015, Liver international : official journal of the International Association for the Study of the Liver.

[8]  V. Ertekin,et al.  Hepatoportal Sclerosis in Childhood: Descriptive Analysis of 12 Patients , 2013, Journal of Korean medical science.

[9]  T. Schiano,et al.  Obliterative Portal Venopathy: A Clinical and Histopathological Review , 2013, Digestive Diseases and Sciences.

[10]  T. Roskams,et al.  Histological features in western patients with idiopathic non‐cirrhotic portal hypertension , 2013, Histopathology.

[11]  John F. Flaherty,et al.  Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study , 2013, The Lancet.

[12]  D. Valla,et al.  Idiopathic noncirrhotic portal hypertension , 2011, Hepatology.

[13]  V. Paradis,et al.  Obliterative portal venopathy: portal hypertension is not always present at diagnosis. , 2011, Journal of hepatology.

[14]  E. Schiff,et al.  Long‐term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B , 2010, Hepatology.

[15]  S. Ben-Dor,et al.  A Critical Role for Ceramide Synthase 2 in Liver Homeostasis , 2010, The Journal of Biological Chemistry.

[16]  George Kitis,et al.  Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. , 2006, Gastroenterology.

[17]  P. Brissot,et al.  Reversibility of hepatic fibrosis in treated genetic hemochromatosis: A study of 36 cases , 2006, Hepatology.

[18]  N. Andrews,et al.  Iron homeostasis and inherited iron overload disorders: an overview. , 2004, Hematology/oncology clinics of North America.

[19]  L. A. D. de Freitas,et al.  Incomplete septal cirrhosis: an enigmatic disease , 2004, Liver international : official journal of the International Association for the Study of the Liver.

[20]  A. Czaja,et al.  Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis. , 2004, Journal of hepatology.

[21]  F. Colina,et al.  Clinicopathological features of nine cases of non‐cirrhotic portal hypertension: current definitions and criteria are inadequate , 2003, Histopathology.

[22]  K. Tsuneyama,et al.  Incomplete septal cirrhosis associated with Wegener's granulomatosis. , 2002, Liver.

[23]  D. Valla,et al.  Idiopathic non-cirrhotic intrahepatic portal hypertension in the West: a re-evaluation in 28 patients , 2002, Gut.

[24]  M. Manns,et al.  Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. , 2002, Gastroenterology.

[25]  M. Sherman,et al.  Regression of human cirrhosis. Morphologic features and the genesis of incomplete septal cirrhosis. , 2000, Archives of pathology & laboratory medicine.

[26]  T. Terada,et al.  Histopathology of the liver in non‐cirrhotic portal hypertension of unknown aetiology , 1996, Histopathology.

[27]  I. Wanless micronodular transpormation (nodular regenerative hyperplasia) of the liver: A report of 64 cases among 2,500 autopsies and a new classification of benign hepatocellular nodules , 1990, Hepatology.

[28]  R. Sciot,et al.  Incomplete septal cirrhosis: histopathological aspects , 1988, Histopathology.

[29]  E. Schiff,et al.  Histological outcome during long-term lamivudine therapy. , 2003, Gastroenterology.

[30]  I. Wanless,et al.  Intrahepatic portal vein sclerosis in patients without a history of liver disease. An autopsy study. , 1982, The American journal of pathology.